Activating an enzyme to treat metabolic disease and cancer
This article was originally published in Start Up
Many companies would like to emulate the success of metformin, the most widely prescribed oral anti-diabetic medication in the world. Metformin helps people control their diabetes primarily by suppressing glucose production in the liver, and it does this by activating an enzyme called AMP-activated protein kinase. The drug’s observed benefits continue inspiring researchers to seek other ways of activating AMPK, but so far no one has been able to match Metformin. NovaTarg Inc. thinks it is on the right track. The start-up has found and is developing compounds that activate AMPK in a tissue-selective way.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.